Results 221 to 230 of about 24,923 (301)

Absorption, distribution, metabolism and excretion of londamocitinib after single‐dose inhaled, intravenous and oral administration in healthy participants

British Journal of Clinical Pharmacology, EarlyView.
Aim Londamocitinib (AZD4604) is an inhaled, selective Janus kinase 1 (JAK1) inhibitor in development for asthma. This open‐label, two‐part, phase I clinical study (NCT06157255) used a radiolabelled microtracer approach to evaluate the absolute bioavailability and the absorption, distribution, metabolism and excretion (ADME) of inhaled londamocitinib ...
Camille Riff, Peter Bold, Maria Heijer, Ryan A. Bragg, Danielle Steele, Tina Jellesmark Jensen, Davinder P. S. Dosanjh, Sabrina I. Hanswijk‐Bartelds, Esther van Duijn, Elwin R. Verheij, Somasekhara Menakuru, Rod Hughes, Helena Dahlbäck   +12 more
wiley   +1 more source

Fructose Promotes Oxidative Stress, Sphingolipid Remodelling and Transient Intestinal Barrier Dysfunction in Differentiated Caco-2 Cells. [PDF]

Nutrients
Serreli G, Melis MP, Guerriero C, Manis C, Tolle G, Sanna G, Orrù G, Fais S, Caboni P, Deiana M.   +9 more
europepmc   +1 more source

Phase 1, open‐label, randomized study of the elecoglipron pharmacokinetic profile in healthy participants under fed and fasted conditions

British Journal of Clinical Pharmacology, EarlyView.
Aims Elecoglipron (AZD5004/ECC5004) is an oral small‐molecule glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) in development for weight management in people living with obesity or overweight and type 2 diabetes. This study aimed to characterize the pharmacokinetics (PK) profiles of two formulations of elecoglipron under fed and fasted conditions ...
Jianfeng Xu, Amina Haggag, Laurie Butcher, Haihui Liu, Wen Chen, Xuefeng Sun, Aruni Jha, Hongtao Yu, Anis Khan, Victoria E. R. Parker, Christer Tannergren, Xiaoliang Pan, Jianfeng Xu, Jingye Zhou   +13 more
wiley   +1 more source

Transcatheter Intervention Is Associated With Visceral Decongestion in Patients With Severe Tricuspid Regurgitation. [PDF]

Clin Cardiol
Putz FJ, Spahn J, Kranert PC, Grewe F, Haus M, Wester M, Bienert V, Trum M, Schach C, Luchner A, Birner C, Unsöld B, Banas MC, Banas B, Maier LS, Debl K, Paulus M, Meindl C.   +17 more
europepmc   +1 more source

Safety and pharmacokinetics of inhaled aloxistatin: A first‐in‐human phase 1 dose escalation trial

British Journal of Clinical Pharmacology, EarlyView.
Aims Aloxistatin (E64d) is a membrane‐permeable cysteine protease inhibitor prodrug that is converted by esterases to the active metabolite E64c (loxistatin). This first‐in‐human study evaluated the safety, tolerability and pharmacokinetics of single ascending doses of inhaled E64d in healthy volunteers.
Sebastian Fähndrich, Franziska Friedrich, Daniel Soriano, Jona Gjeloshi, Björn C. Frye, Xuan Phuoc Nguyen, Lydia Herbstritt, Caroline von Spee‐Mayer, Britta Lang, Fabrice Nollevaux, Andreas Hoheisel, Dorothee Winterberg, Armin Braun, Thomas Epting, Christine Contini, Karl Winkler, Thomas Reinheckel, Franziska C. Trudzinski, Gernot Rohde, Daiana Stolz, Robert Bals, Martin J. Hug, Sebastian Wirtz, Christoph Peters, Carolin Jenkner   +24 more
wiley   +1 more source

Mitral Transcatheter Edge-to-Edge Repair in Ventricular Functional Mitral Regurgitation and Very Severe Left Ventricular Dysfunction. [PDF]

JACC Adv
Omote K, Yamamoto M, Sugiura A, Shimura T, Kubo S, Izumi Y, Saji M, Asami M, Enta Y, Shirai S, Izumo M, Mizuno S, Watanabe Y, Amaki M, Kodama K, Otsuki H, Naganuma T, Bota H, Ohno Y, Yamawaki M, Hachinohe D, Ueno H, Nakazawa G, Otsuka T, Hayashida K, OCEAN-Mitral Investigators.   +25 more
europepmc   +1 more source

Pharmacokinetic and pharmacodynamic interaction of enavogliflozin, a sodium‐glucose cotransporter 2 inhibitor, with glimepiride and metformin in healthy participants

British Journal of Clinical Pharmacology, EarlyView.
Aims Enavogliflozin, a sodium‐glucose cotransporter 2 inhibitor, is expected to be coadministered with antihyperglycaemic drugs with different mechanisms of action. This study aimed to investigate the pharmacokinetic (PK) and pharmacodynamic (PD) interactions between enavogliflozin, glimepiride and metformin.
Kyungrin Chang, Yoonjin Kim, Daye Jung, Jae Min Cho, Joo‐Youn Cho, SeungHwan Lee   +5 more
wiley   +1 more source

Chinese TEER Innovation

JACC: Asia
openaire   +1 more source